In a patient with an estimated glomerular filtration rate of 40 mL/min (moderate renal impairment), which antiviral medication(s) for chronic hepatitis B are safe to use?

Tenofovir Alafenamide (TAF) is the preferred antiviral for chronic hepatitis B in patients with GFR 40 mL/min

For a patient with GFR 40 mL/min and chronic hepatitis B, tenofovir alafenamide (TAF) 25 mg daily is the optimal choice, requiring no dose adjustment and offering superior renal safety compared to other nucleos(t)ide analogues. 1, 2

Treatment Options by Renal Safety Profile

First-Line: Tenofovir Alafenamide (TAF)

• No dose adjustment needed for GFR 30-80 mL/min 1, 2
• Demonstrated improved renal outcomes compared to tenofovir disoproxil fumarate (TDF) in patients with renal impairment 3
• At 96 weeks, median eGFR change was only +1.0 mL/min in patients with moderate renal impairment 3
• Recent evidence shows TAF superior to entecavir for preserving renal function, with significantly better eGFR at 48 weeks 4, 5

Alternative: Entecavir

If TAF is unavailable, entecavir requires dose adjustment for GFR 30-49 mL/min:

• 0.25 mg daily OR 0.5 mg every 48 hours for treatment-naïve patients 1, 2
• 0.5 mg daily OR 1 mg every 48 hours for lamivudine-resistant patients 1, 2

However, entecavir shows greater eGFR decline compared to TAF. At 48 weeks, entecavir-treated patients had significantly lower eGFR (106.10 vs 111.01 mL/min/1.73 m²) 5. Switching from entecavir to TAF in patients with declining renal function resulted in significant eGFR improvement (83.60 to 93.39 mL/min/1.73 m²) within 12 weeks 4.

Avoid These Options

Tenofovir Disoproxil Fumarate (TDF)

• Requires dose reduction to 300 mg every 48 hours for GFR 30-49 mL/min 1, 2
• Associated with progressive eGFR decline in patients with renal impairment 6
• Significantly worse renal outcomes than TAF, with median eGFR decline of -5.0 mL/min vs -0.3 mL/min for TAF over 96 weeks 2
• Should be avoided in patients with pre-existing renal dysfunction 2

Adefovir

• Requires dose reduction to 10 mg every 48 hours for GFR 20-49 mL/min 1, 2
• Higher nephrotoxic potential than other nucleotide analogues 7
• Not recommended as first-line therapy

Monitoring Requirements

For any nucleos(t)ide analogue in patients with GFR 30-60 mL/min:

• Serum creatinine and eGFR every 3 months during first year 7, 2
• Every 6 months thereafter if stable 7
• Serum phosphate monitoring if using TDF (check for levels <2 mg/dL) 7
• More frequent monitoring (monthly for first 3 months) if patient has additional risk factors: decompensated cirrhosis, poorly controlled hypertension, diabetes, or concomitant nephrotoxic drugs 7

Critical Pitfalls to Avoid

1. Do not use lamivudine monotherapy - high resistance rates make it unsuitable despite favorable renal profile 7
2. Do not use telbivudine - while it may improve eGFR 6, risk of myositis and CK elevation outweighs benefits 1
3. Avoid peginterferon - not recommended in moderate renal impairment and requires complex dose adjustments 1
4. Do not delay treatment - HBV infection itself increases KD risk 2.18-fold, and early antiviral treatment reduces this risk (HR 0.61) 8

Special Considerations

• Urinary β2-microglobulin may detect early tubular dysfunction before eGFR changes, with 56.2% of CHB patients showing abnormalities 9
• Male patients require closer renal monitoring 9
• If patient has concomitant hypertension, diabetes, or obesity, cumulative KD risk by age 75 reaches 19% vs 6% without HBV, making aggressive antiviral therapy even more critical 8